Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd. (NYSE: BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders. As part of the collaboration, Bexorg's novel whole-brain discovery platform will be used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven.
Bexorg's whole-brain discovery platform is the only technology capable of perfusing isolated, cadaver human and pig brains with custom-made artificial blood, thereby restoring metabolic and molecular activity for prolonged periods. Bexorg's founders developed the whole-brain perfusion technology at Yale University. Using it, the company can extract high-resolution transcriptomic, proteomic, and metabolic insights in disease-relevant states. With this information, Bexorg is building the largest and most physiologically relevant datasets in human neurodegeneration to enable machine learning and artificial intelligence (AI)-centered CNS drug discovery and development. This breakthrough aims to provide unparalleled insights into human brain molecular activity and advances in the understanding of CNS disorders.
'Our technology enables preclinical testing of almost any therapeutic in metabolically active whole human brains, whether diseased or non-diseased, providing a significant advantage over any other preclinical model in neuroscience,' said Zvonimir Vrselja, MD, PhD, CEO and Co-founder at Bexorg. 'Our ability to collect longitudinal data from our whole-brain discovery platform allows us to validate new targets and biomarkers and understand the pharmacokinetic and pharmacodynamic profiles and potential safety and effectiveness of drugs before going into the clinic. We are thrilled to team up with Biohaven to help advance two preclinical programs and potentially unlock a faster, more precise path to new CNS therapies.'
'The lack of robust translational preclinical models that adequately capture the complexity of human brain structure and function, including the architecture and dynamics of neural networks comprised of billions of neurons and glial cells and the trillions of connections that exist between them, and account for physiological gradients of drug exposure throughout the brain associated with distinct profiles of drug transport across the blood-brain barrier, has, until now, severely handicapped CNS drug discovery and development,' said Bruce D. Car, DVM, PhD, DACVP, Chief Scientific Officer at Biohaven. 'Bexorg's novel platform effectively overcomes the myriad deficiencies inherent in this translational gap, permitting unprecedented and detailed insights into the CNS pharmacology, dosimetry, and potential efficacy of drug candidates before advancing to costly and time-consuming clinical trials.'
As part of the collaboration, Bexorg aims to deliver insights from systemic delivery of Biohaven's therapeutics, including analysis of pharmacokinetics, pharmacodynamics, and mechanism of action. Data generated from the platform may also potentially point to the responsiveness of patient subpopulations and identify novel biomarkers to inform clinical trials. Financial terms of the collaboration were not disclosed.
About BiohavenBiohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and nonclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. For more information, visit www.biohaven.com.
About BexorgBexorg is a privately held techbio company with the first-ever full-stack tech platform to support central nervous system (CNS) drug discovery and development in the human brain in a way that has not been possible before. Bexorg is building a drug discovery artificial intelligence (AI) loop based on its proprietary wet-lab platform, BrainEx, which enables restoration of molecular activity in postmortem human brains to generate high-fidelity, clinically predictive data, model drug response, and create a foundation model for CNS discovery. The company is generating large volumes of human brain data to train predictive models across diseases. Bexorg is building an AI engine, XO Digital, which learns from each experiment, creating a closed-loop system of in-silico prediction and wet-lab validation. With this fully integrated platform, Bexorg is setting a new standard for CNS translational and discovery research. In collaboration with the National Institutes of Health (NIH), Bexorg's founders have been at the forefront of bioethics in postmortem brain molecular recovery research, and the company has an independent board comprised of bioethics leaders to ensure its operations maintain the highest standards. Bexorg is strategically partnering with leading neuroscience companies to integrate its platform into clinical development programs, as well as advancing in-house neurodegeneration assets. Visit us at www.bexorg.com and follow us on LinkedIn to learn more.
Biohaven's Forward-looking StatementsThis news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'next generation', 'most', 'unparalleled', 'largest', significant', 'novel', 'unprecedented', and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
CONTACT: Bexorg Media Contact: Adam Silverstein SCIENT PR adam@scientpr.com Biohaven Contacts: Investor Contact: Jennifer Porcelli Vice President, Investor Relations jennifer.porcelli@biohavenpharma.com +1 (201) 248-0741 Media Contact: Mike Beyer Sam Brown Inc. mikebeyer@sambrown.com +1 (312) 961-2502

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

2 hours ago

• Business Upturn

Can't Wait for XRP to Hit $10? PFMCrypto Launches 1-Day Cloud Mining Contract With $10 Free Bonus

Farington, England, June 21, 2025 (GLOBE NEWSWIRE) — Despite growing enthusiasm in the XRP community, the long-awaited $10 milestone remains out of reach. XRP continues to fluctuate between $2.05 and $2.33, showing signs of consolidation rather than breakout. In response, PFMCrypto has introduced a new 1-day XRP cloud mining contract, providing holders with a smart and simple way to generate daily income—even as they wait for the next major price surge. New users receive a $10 signup bonus, enabling them to start mining XRP with no upfront investment. Explore the future of XRP mining now at: One-Day Contract, Same-Day Rewards Unlike traditional mining that relies on expensive hardware and technical know-how, PFMCrypto's XRP cloud mining model is fully remote and designed to simulate yield through proprietary infrastructure and AI-driven optimization. The newly launched 1-day mining contract is the most accessible option yet, letting users activate a plan using their $10 welcome bonus and receive $0.66 in daily XRP rewards—with no cost, no setup, and no risk. This short-term mining model allows XRP holders to earn predictable returns while staying engaged during sideways markets. Key Features of PFMCrypto's XRP Cloud Mining Contracts – No Hardware Required: Accessible to all users without the need for mining equipment or technical setup – Daily Payouts: Earn mining rewards daily based on your contract participation – Secure Custody: Assets are protected under PFMCrypto's industry-grade security standards – Flexible Contract Durations: Choose from short-, mid-, or long-term options to match your investment strategy Flexible Plans for All Investors PFMCrypto offers over 10 unique mining contracts to suit every investor profile—from curious beginners to seasoned holders seeking high-yield options: $10 Contract – 1 Day – Earn $0.66 (free with signup bonus) $100 Contract – 2 Days – Earn $3.00 daily + $2 bonus payout $1,000 Contract – 9 Days – Earn $13.10 daily $5,000 Contract – 30 Days – Earn $78.50 daily For long-term XRP holders, these plans offer a practical way to remain active in the ecosystem and generate steady returns while the token builds momentum toward higher price targets. Click here to explore the $10 XRP mining contract. What Sets PFMCrypto's XRP Mining Contracts Apart? – 100% Remote Access: No equipment, no tech skills—just log in and activate your plan – Capital Protection: Contracts guarantee full principal return upon maturity – AI-Powered Profitability: Yield optimization ensures profitability even during price stagnation – Daily Rewards: Predictable XRP payouts improve cash flow and reduce volatility risk How to Start Mining on PFMCrypto Register an Account: Get a $10 bonus plus $0.66 daily login rewards Select a Mining Contract: Activate a plan using your bonus or choose your own Start Mining: Sit back and earn—rewards are credited daily, automatically A Smarter Way to Wait: Income While XRP Consolidates Founded in 2018, PFMCrypto has been at the forefront of cloud-based crypto mining, democratizing access to passive income through secure, AI-powered, and environmentally conscious infrastructure. The platform is built to help users mine leading cryptocurrencies—like XRP, BTC, SOL, and DOGE—without the need for expensive rigs or in-depth technical knowledge. 'The path to $10 may take time, but XRP holders shouldn't have to wait empty-handed, ' said a PFMCrypto spokesperson. ' Our 1-day mining contracts are designed to give users a simple, low-risk opportunity to generate daily XRP returns—while staying engaged with the ecosystem.' Don't wait for the next rally to start earning—activate your XRP mining contract today at Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Yahoo

5 hours ago

• Yahoo

Citi Increases PT on Oracle (ORCL), Keeps Neutral

Oracle Corporation (NYSE:ORCL) is one of the 10 software stocks analysts are upgrading. On June 12, Citi raised the price target on the company's stock to $196 from $186, while keeping a 'Neutral' rating. The firm believes that Oracle Corporation (NYSE:ORCL)'s Q4 2025 results are incrementally positive considering fiscal 2026 demand. That being said, the company's near-term earnings and FCF estimates have been falling. A team of IT professionals meticulously crafting a large-scale enterprise performance management system. As per Citi, Oracle Corporation (NYSE:ORCL) posted a strong Q4 2025, while it saw modest bookings growth. However, this was overshadowed by a strong fiscal 2026 sales outlook amidst accelerating cloud, remaining performance obligation, and total revenue growth, added the analyst. Oracle Corporation (NYSE:ORCL) expects its total cloud growth rate, applications plus infrastructure, to increase from 24% in FY 2025 to more than 40% in FY 2026. Notably, the Cloud Infrastructure growth rate is anticipated to increase from 50% in FY 2025 to more than 70% in FY 2026, while RPO is projected to grow over 100% in FY 2026. Also, Oracle Corporation (NYSE:ORCL) anticipates triple-digit MultiCloud revenue growth to continue in FY 2026. Ariel Investments, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Lastly, global leader in enterprise software, Oracle Corporation (NYSE:ORCL), traded lower alongside the broader technology sector due to macroeconomic uncertainty and in particular, the near-term prospects for artificial intelligence investment (AI) spending. As a result, ORCL reported weaker than expected quarterly earnings results. Nonetheless, management expects double-digit growth for fiscal 2026 and 2027, citing significant demand for its cloud and AI capabilities. This supports our view that ORCL's positioning as the leading provider of database software and cloud-based infrastructure is entrenched, making it a key beneficiary of global demand for generative AI development.' While we acknowledge the potential of ORCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORCL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.

Yahoo

8 hours ago

• Yahoo

Zeta Global (ZETA) Jumps 12.6% on Untapped AI Opportunities

Zeta Global Holdings Corp. (NYSE:ZETA) is one of the Zeta Global Holdings rallied by 12.63 percent on Friday to end at $14.18 apiece as investors snapped up shares following a study that marketing companies are lagging behind AI execution vis-a-vis its ambitions. In its study called 'It's Time to Get Serious About AI's Business Value,' Zeta Global Holdings Corp. (NYSE:ZETA) said that while many marketing organizations have begun implementing AI, most are still in the early stages of building the data, skills and systems required to scale it effectively and realize its full enterprise potential. Based on a survey of 300 North American marketing technology decision-makers, the study found that 62 percent of organizations described their current AI deployment as 'limited' or 'moderate.' The study was viewed by investors as a huge potential and opportunity for Zeta Global Holdings Corp. (NYSE:ZETA) to tap. 'Marketing should be at the front lines of the AI revolution, but many teams are held back by fragmented data, legacy systems, and skills gaps,' said Chairman and CEO David Steinberg. A marketing manager looking at the data dashboard of a marketing automation software showing successful campaign results. 'This study reinforces what we hear every day: marketers don't need more AI promises; they need practical, scalable ways to turn AI into better performance.' While we acknowledge the potential of ZETA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data